Premium
Successful topical treatment of anal giant condylomata acuminata in an infant
Author(s) -
Giancristoforo Simona,
Diociaiuti Andrea,
Tchidjou Hyppolite K.,
Lucchetti Maria Chiara,
Carnevale Claudia,
Rotunno Roberta,
D'Argenio Patrizia,
El Hachem Maya
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13624
Subject(s) - imiquimod , medicine , dermatology , cryotherapy , lesion , genital warts , human papillomavirus , surgery , human immunodeficiency virus (hiv) , syphilis , family medicine
Anogenital condylomata acuminata are induced by human papillomavirus (HPV) and they rarely manifest in immunocompetent children. Therapeutic options depend on patient's age and general conditions and extension of the lesions. However, management is still a challenge and recurrences are frequent. Cryotherapy, laser, and surgical treatments in children are painful and frequently require general anesthesia. Imiquimod is a topical immune response modifier and constitutes a noninvasive alternative for the treatment of anogenital condylomata acuminata. Here, we report an infant admitted to our hospital with a giant vegetative papillomatous lesion on the perianal region surrounded by small satellites papules. PCR for HPV confirmed the clinical diagnosis of giant condylomata acuminata due to HPV type 6. The child has been successfully treated with topical 5% imiquimod cream without side effects. Although topical imiquimod is not licensed for pediatric age, this report highlights the potential benefits of its use in selected pediatric cases.